Cevostamab Biosimilar – Anti-FCRL5;CD3 mAb – Research Grade from ProteoGenix; catalogue PX-TA1823; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Cevostamab Biosimilar, also known as Anti-FCRL5,CD3 mAb, is a novel antibody that has been developed as a potential therapeutic agent for various diseases. In this article, we will discuss the structure, activity, and potential applications of this biosimilar in detail.
Cevostamab Biosimilar is a monoclonal antibody that is composed of two different types of proteins: the Fc region and the Fab region. The Fc region is responsible for the effector functions of the antibody, while the Fab region binds to the target antigen.
The Fc region of Cevostamab Biosimilar is derived from human IgG1, which is known to have a longer half-life in the body compared to other antibody isotypes. This allows for a prolonged therapeutic effect of the antibody. The Fab region is composed of two heavy chains and two light chains, which are responsible for binding to the target antigen.
The main activity of Cevostamab Biosimilar is its ability to bind to FCRL5, a protein that is highly expressed on the surface of certain immune cells, such as B cells and T cells. By binding to FCRL5, Cevostamab Biosimilar can modulate the immune response and potentially treat various diseases.
In addition to its ability to bind to FCRL5, Cevostamab Biosimilar also has a CD3 binding domain. CD3 is a protein found on the surface of T cells and is involved in T cell activation. By binding to CD3, Cevostamab Biosimilar can activate T cells and enhance their immune response.
Cevostamab Biosimilar has shown promising results in preclinical studies for the treatment of various diseases, including autoimmune disorders, cancer, and infectious diseases.
FCRL5 has been found to be overexpressed on B cells in patients with autoimmune disorders, such as rheumatoid arthritis and systemic lupus erythematosus. By targeting FCRL5, Cevostamab Biosimilar can potentially modulate the immune response and treat these diseases.
FCRL5 is also highly expressed on the surface of cancer cells, making it a potential therapeutic target for cancer treatment. By binding to FCRL5, Cevostamab Biosimilar can potentially induce cell death in cancer cells and inhibit tumor growth.
infectious diseases, such as viral infections. By activating T cells through its CD3 binding domain, Cevostamab Biosimilar can enhance the immune response and potentially clear viral infections.
Cevostamab Biosimilar, also known as Anti-FCRL5,CD3 mAb, is a novel antibody with the potential to treat various diseases. Its unique structure and dual activity make it a promising therapeutic agent for autoimmune disorders, cancer, and infectious diseases. Further clinical studies are needed to fully evaluate the efficacy and safety of this biosimilar, but early results are promising.
ProteoGenix catalogue number PX-TA1823. For research use only.
Target: Cevostamab Biosimilar – Anti-FCRL5;CD3 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Buffer: PBS buffer PH7.5; Applications: WB, ELISA.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Cevostamab Biosimilar – Anti-FCRL5;CD3 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
